Alicia Irurzun-Lafitte has departed from a principal position at M Ventures for a partner role at another pharmaceutical firm's corporate venturing fund, UCB Ventures.
Alicia Irurzun-Lafitte, formerly a principal at M Ventures, the corporate venture capital unit for Germany-based drugs producer Merck Group, has joined UCB Ventures, Belgium-based biopharmaceutical company UCB’s corporate venturing subsidiary, as a partner.
UCB Ventures is a €150m ($168m) fund launched in 2017 that invests in early-stage startups developing therapeutics focused on immunological aspects of neurodegenerative and musculoskeletal disorders.
Irurzun-Lafitte, who will be based in Boston, in the United States, will scout and conduct US-based deals in collaboration with UCB…
